论文部分内容阅读
目的:在原核细胞中表达具有生物活性的重组水蛭素变异物1(rHV1)并进行重组产物的分离纯化研究。方法:以质粒pBV220为载体,在大肠杆菌DH5α中表达rHV1,发色底物法测定其抗凝血酶生物活性;利用超滤、DEAE-SephadexA-50以及凝血酶亲合层析进行重组产物的分离纯化。结果:在大肠杆菌中获得了rHV1的活性表达,表达量约占总蛋白的16.9%,活力达到20~30ATU/ml培养液;初步的纯化研究得到了具抗凝生物活性的rHV1纯品,SDS聚丙烯酰胺凝胶电泳呈单一条带。结论:重组水蛭素变异物1的活性表达及其分离纯化研究填补了国内空白,为研制国产高效重组抗凝药物带来希望。
Objective: To express bioactive hirudin mutant 1 (rHV1) in prokaryotic cells and to study the isolation and purification of recombinant hirudin. Methods: The plasmid pBV220 was used as a vector to express rHV1 in E. coli DH5α, and its antithrombin biological activity was assayed by chromogenic substrate method. The recombinant protein was characterized by ultrafiltration, DEAE-Sephadex A-50 and thrombin affinity chromatography Isolation and Purification. Results: The expression of rHV1 in Escherichia coli was about 16.9% of the total protein and its activity was 20 ~ 30ATU / ml. The purified rHV1 with anticoagulant activity SDS polyacrylamide gel electrophoresis showed a single band. CONCLUSION: The study on the activity of recombinant hirudin mutant 1 and its isolation and purification have filled the gap in our country and brought hope for the development of highly efficient recombinant anticoagulant drugs in China.